PREEKLAMPSIYA KASALLIGIDA MUHIM BIOKIMYOVIY MARKERLAR (C-REAKTIV OQSIL, LAKTATDEGIDROGENAZA, MOCHEVINA VA KREATININ)NING O‘ZGARISH DINAMIKASI

Shaxnoza Sharipova

Authors

Shaxnoza Sharipova Buxoro davlat tibbiyot instituti tayanch doktoranti Author

Keywords:

preeklampsiya, C-reaktiv oqsil, laktatdegidrogenaza, mochevina, kreatinin

Abstract

Preeklampsiyada (PE) endotelial disfunksiya va poliorgan yetishmovchiligini aks ettiruvchi biokimyoviy markerlar - C-reaktiv oqsil (CRP), laktatdegidrogenaza (LDG), mochevina va kreatininning trimestrlar bo‘yicha dinamikasi o‘rganildi. Material va usullar. Prospektiv tadqiqotga 102 nafar homilador ayol jalb etildi: nazorat guruhi (n=30), erta tashxislangan va majmuaviy davolash olib borilgan guruh (n=32) va erta tashxislanmagan guruh (n=40). CRP, LDG, mochevina va kreatinin fermentativ hamda immunoturbidimetrik usulda trimestrlar kesimida aniqlandi. Ma’lumotlar SPSS 26.0 da ANOVA va Kruskal–Uollis mezonlari bilan qayta ishlandi; p<0,05 ishonchli deb qabul qilindi. Natijalar. Barcha markerlar 3-guruhda eng yuqori bo‘ldi. III trimestrda 3-guruhda CRP 32,9±3,8 mg/l (nazoratga nisbatan 5,2 baravar), LDG 648,9±34,0 ED/l (2,88 baravar), mochevina 7,1±0,6 mmol/l (2,4 baravar), kreatinin 107,4±5,4 mkmol/l (2,0 baravar) gacha oshdi (p<0,05). LDG ning 400 ED/l dan oshishi to‘qima gipoksiyasi va gemolizdan, kreatininning 100 mkmol/l dan oshishi buyrak disfunksiyasidan dalolat berdi. Davolangan 2-guruhda barcha markerlar ishonchli darajada pastroq bo‘ldi (p<0,05). Xulosa. CRP, LDG, mochevina va kreatininni majmuaviy va dinamik baholash PE og‘irligini aniqlash hamda HELLP-sindrom va poliorgan yetishmovchiligini erta bashorat qilishda muhim klinik ahamiyatga ega.

Downloads

Download data is not yet available.

References

1. Rana S., Lemoine E., Granger J.P., Karumanchi S.A. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res. 2019;124(7):1094–1112.

2. Chappell L.C., Cluver C.A., Kingdom J., Tong S. Pre-eclampsia. Lancet. 2021;398(10297):341–354.

3. Burton G.J., Redman C.W., Roberts J.M., Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019;366:l2381.

4. Haram K., Svendsen E., Abildgaard U. The HELLP syndrome: clinical issues and management. A review. BMC Pregnancy Childbirth. 2009;9:8.

5. ACOG. Gestational Hypertension and Preeclampsia: Practice Bulletin No. 222. Obstet Gynecol. 2020;135(6):e237–e260.

6. Gary A., Dildy G.A., et al. Lactate dehydrogenase as a marker of severity in preeclampsia and HELLP syndrome. J Perinatol. 2016.

7. Ceyhan T., Beyan C., Baser I., et al. The effect of pre-eclampsia on complete blood count, platelet count and mean platelet volume. Ann Hematol. 2006;85(5):320–322.

8. Bramham K., Parnell B., Nelson-Piercy C., et al. Chronic kidney disease and pregnancy outcomes: systematic review and meta-analysis. BMJ. 2013;347:f6564.

9. Magee L.A., Brown M.A., Hall D.R., et al. The 2021 ISSHP classification, diagnosis and management recommendations for pregnancy hypertension. Pregnancy Hypertens. 2022;27:148–169.

10. Poon L.C., Shennan A., Hyett J.A., et al. The FIGO initiative on pre-eclampsia: first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Suppl 1):1–33.

11. World Health Organization. WHO recommendations on prevention and treatment of pre-eclampsia and eclampsia. Geneva: WHO; 2011.

12. Ayupova F.M., Karimova N.A. Preeklampsiyada biokimyoviy markerlarning diagnostik ahamiyati. O‘zbekiston tibbiyot jurnali. 2022;(2):45–50.